Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma

M V Madden, J E J Krige, S Bailey, S J Beningfield, C Geddes, I D Werner, J Terblanche

Abstract
Lipiodol injected into the hepatic artery is selectively retained in hepatomas so has been used as a vehicle for cytotoxic drugs. This study compared treatment with 5-epidoxorubicin emulsified in lipiodol and infused into the hepatic artery with symptomatic treatment alone in a randomised trial. Of 136 patients with hepatoma 78 (57%) were not eligible, eight (6%) refused to take part, and 50 entered the trial (chemotherapy: n=25, symptomatic treatment: n=25). The two groups had similar prognostic indices. Seven of 25 patients allocated to chemotherapy were unable to receive it. The slight survival disadvantage associated with chemotherapy was not significant (median survival 48 days compared with 51 days, log rank χ²=0·07, p>0·05). Patients given chemotherapy spent significantly longer in hospital, however (median three days compared with one, p=0·0008). Changes in symptoms and indices of tumour growth did not differ significantly between the two groups. It is concluded that infusion of 5-epidoxorubicin emulsified in lipiodol for hepatoma increased morbidity but did not affect survival. In addition, most patients were unsuitable for this treatment because of advanced disease. The patients in the trial had a short median survival time so the conclusions may not be valid for other patients with hepatoma.

Hepatomas are seldom resectable and usually incurable. Iodised poppyseed oil (lipiodol) injected into the hepatic artery is selectively retained in such tumours, and there have been uncontrolled reports that an infusion of cytotoxic agents emulsified in lipiodol into the hepatic artery may increase survival of patients with hepatoma.1,2 The aim of this study was to compare the efficacy of such a regimen with our standard palliative treatment in a randomised trial.

Patients and methods
All patients seen at Groote Schuur Hospital between 1 January 1987 and 30 November 1991 who either had abnormal α fetoprotein estimations or who were being investigated for hepatoma were considered for inclusion in the trial. The diagnosis was confirmed if two of the following criteria were met: a 10-fold increase in serum α fetoprotein concentration, cytological or histological appearance compatible with a diagnosis of hepatoma; or angiographic findings that suggested hepatoma.3 Patients were eligible for the trial provided that none of the criteria listed in Table I were applicable. Spread of tumour outside the liver was sought by a chest radiograph as well as an ultrasound scan and a computed tomogram of the abdomen. Patients were randomised to receive either chemotherapy or symptomatic treatment alone by opening consecutive sealed opaque envelopes, which had been numbered according to a balanced computer generated random sequence.

The number of patients to be studied was calculated by reference to the length of survival of the disease.4 Two of five patients given chemotherapy and four of five who received symptomatic treatment alone survived 30 days. We wanted to be 80% certain of detecting a difference in survival of this size between the two groups and 95% sure that any difference detected was not simply a result of chance.5 A total of 46 patients was needed to establish this, and the number of cases was rounded up to 50. The protocol remained unchanged. Survivors had computed tomograms at intervals of one month to monitor progression of the tumour.

Chemotherapy, which consisted of one dose of 5-epidoxorubicin (60 mg/m²) emulsified in 6 ml lipiodol and 5 ml meglumine iothalamate, was given through a catheter that had been placed in the hepatic artery during arteriography; this was repeated four weeks later if the patient still satisfied the entry criteria of the trial. The progress of the patients was evaluated monthly until they died.

The end point of the trial was length of survival after randomisation. Patients were also asked to estimate the amount of pain that they had and their appetite at entry and at each evaluation, on a linear analogue scale. The purpose, risks, and benefits associated with the trial were explained to patients who were eligible for entry by the trial coordinator using a form approved by the Ethics and Research Committee of the Medical Faculty of the University, which had also approved the trial design. The survival of the two groups was compared by the Kaplan-Meier log rank method. The effect of the trial’s size on the validity of the findings was assessed by calculating confidence limits.6 Quantitative data that were not normally distributed were compared by Wilcoxon’s rank sum test.

Results
Of the 136 patients considered for entry to the trial during the 58 months of the study, 78 (57%) were not eligible; a further eight patients refused to participate (Table I).
Those patients who were randomised to receive chemotherapy had similar prognostic indices to those allocated to receive symptomatic treatment alone (Tables II, III, and IV). Patients in the chemotherapy group survived for a median of three days less than those allocated to symptomatic treatment. This difference was not significant (median 48 days (range 1–504) compared with 51 days (range 0–607), log rank $\chi^2=0.07$, Kaplan-Meier, Fig). Patients who received chemotherapy spent significantly longer in hospital after diagnosis (median three days (range 1–17) compared with one (range 0–9), $p=0.0008$, Wilcoxon’s rank sum test). The changes in patients’ assessments of pain and appetite during their illness did not differ significantly between the two groups. The median pain score (maximum 100) in the chemotherapy group increased from 7 (range 1–99) at entry to 24 (range 6–70) after one month and from 10 (range 1–98) to 27 (range 1–89) among those who received symptomatic treatment. The median appetite score worsened from 43 (range 1–99) to 16 (range 5–25) in the chemotherapy group and from 26 (range 1–99) to 19 (range 2–99) in the group that received symptomatic treatment. Objective measures of progression of the tumour did not differ between the two groups: the computed tomogram at the one month follow up showed that the tumours had increased in size in five of 25 patients in the chemotherapy group and six of 25 who had symptomatic treatment. The mean rises in serum $\alpha$ fetoprotein concentrations during the month after entry were 10% and 11%, respectively.

Seven of 25 patients allocated to receive chemotherapy did not receive it (inability to cannulate the hepatic artery, $n=3$; withdrew consent for angiogram, $n=2$; coagulopathy, $n=1$; early death, $n=1$). Of the 18 patients who received an initial dose of chemotherapy three

<table>
<thead>
<tr>
<th>TABLE I Reasons for exclusion of 86 patients from the trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>ECOG stage 4 (bedridden)</td>
</tr>
<tr>
<td>Home too remote for follow up</td>
</tr>
<tr>
<td>Age &gt;70 years</td>
</tr>
<tr>
<td>Extrahepatic tumour</td>
</tr>
<tr>
<td>Diagnosis not proved</td>
</tr>
<tr>
<td>Serious heart disease</td>
</tr>
<tr>
<td>Refused consent to trial</td>
</tr>
<tr>
<td>Chose traditional healer</td>
</tr>
<tr>
<td>Treated with radiotherapy</td>
</tr>
<tr>
<td>Tumour resected</td>
</tr>
<tr>
<td>Abnormal hepatic artery</td>
</tr>
<tr>
<td>Variceal bleeding</td>
</tr>
<tr>
<td>Pulmonary tuberculosis</td>
</tr>
<tr>
<td><strong>86 (100)</strong></td>
</tr>
</tbody>
</table>

remained well enough to receive a second dose one month later.

The survival of black patients ($n=23$, median 54 days, range 0–504) did not differ significantly from that of the mixed race and white patients ($n=27$, median 43 days, range 0–607, log rank $\chi^2=0.15$, Kaplan-Meier).

Our conclusion that the treatment is of no value is based on a small number of patients so it is important to assess the validity of the finding. The median survival time for untreated cases was 51 days while treated patients lived for a median time of 48 days. We arbitrarily assumed that a clinician would recommend the treatment if a treated patient were at least twice as likely as a control patient to survive beyond 50 days. Excluding the three patients lost to follow up, the likelihood of a treated patient living beyond 50 days was 92% of a control patient’s likelihood (odds ratio 0.923). From the 47 patients on which this odds ratio is based, one can be 95% confident that the true odds ratio lies between 0.29 and 2.91. Furthermore, the likelihood of the true odds ratio being greater than 2, when our hypothetical clinician would recommend treatment, is only 0.09 or 9%. Thus despite its small size this trial shows that the likelihood that the treatment prolongs survival to a clinically important extent in hepatoma patients is fairly low.

**Discussion**

Targeted chemotherapy with 5-epidoxorubicin and lipiodol did not improve survival in this series of patients with hepatoma, nor did it reduce the mean tumour size or the mean serum $\alpha$ fetoprotein concentration. Assessment of the quality of life from the patients’ own ratings of their pain and appetite showed that symptoms seemed to progress equally rapidly in both groups, which suggests that the chemotherapy had no placebo effect either. The significantly longer hospital stay associated with chemotherapy (three days compared with one day) may seem a trivial disadvantage, but when the median survival is only 50 days it is important. All we have shown therefore is increased morbidity associated with the chemotherapy. Previous optimistic reports of this treatment were the result of uncontrolled studies. Random control studies of embolisation with and without chemotherapy have produced little evidence that any of

<table>
<thead>
<tr>
<th>TABLE II Comparability of the two groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemotherapy (n=25)</td>
</tr>
<tr>
<td>Male:female</td>
</tr>
<tr>
<td>Black:mixed race:white</td>
</tr>
<tr>
<td>Median age in years (range)</td>
</tr>
<tr>
<td>Okuda prognostic stage:</td>
</tr>
<tr>
<td>I</td>
</tr>
<tr>
<td>II</td>
</tr>
<tr>
<td>III</td>
</tr>
<tr>
<td>Median ECOG performance rating (range)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TABLE III Okuda prognostic grading*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Factor</td>
</tr>
<tr>
<td>Tumour &gt;50% of liver area</td>
</tr>
<tr>
<td>Ascites present</td>
</tr>
<tr>
<td>Serum albumin &lt;30 g</td>
</tr>
<tr>
<td>Serum bilirubin &gt;50 umol/l</td>
</tr>
</tbody>
</table>

*Modified from Okuda et al.

<table>
<thead>
<tr>
<th>TABLE IV Eastern Cooperative Oncology Group performance rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 Fully active</td>
</tr>
<tr>
<td>1 Ambulatory, capable of light work</td>
</tr>
<tr>
<td>2 In bed &lt;50% of the time, capable of self care but not work</td>
</tr>
<tr>
<td>3 In bed &gt;50% of the time, capable of only limited self care</td>
</tr>
<tr>
<td>4 Completely bedridden</td>
</tr>
</tbody>
</table>

**Discussion**

Targeted chemotherapy with 5-epidoxorubicin and lipiodol did not improve survival in this series of patients with hepatoma, nor did it reduce the mean tumour size or the mean serum $\alpha$ fetoprotein concentration. Assessment of the quality of life from the patients’ own ratings of their pain and appetite showed that symptoms seemed to progress equally rapidly in both groups, which suggests that the chemotherapy had no placebo effect either. The significantly longer hospital stay associated with chemotherapy (three days compared with one day) may seem a trivial disadvantage, but when the median survival is only 50 days it is important. All we have shown therefore is increased morbidity associated with the chemotherapy. Previous optimistic reports of this treatment were the result of uncontrolled studies. Random control studies of embolisation with and without chemotherapy have produced little evidence that any of
the treatments that have been tested are benefi-
cial. Thus a randomised comparison in 42
patients between symptomatic treatment and
embolisation with doxorubicin plus gelatin
spoon showed no difference in survival. A
random comparison between three treatment
regimens in 63 patients (monthly hepatic arterial
embolisation, a single embolisation followed by
monthly intravenous 5-fluorouracil, and
monthly intravenous 5-fluorouracil alone) showed a significantly greater likelihood of
survival after treatment with repeated embolisa-
tion when compared with 5-fluorouracil alone.
This benefit was confined to the period from
eight to 22 months after treatment and although
embolisation was better than 5-fluorouracil it
was not better than a single embolisation
followed by 5-fluorouracil.

Two sources of bias in this study may make it
less relevant to patients with hepatoma in other
countries. Firstly, 46% of the patients were
black. Hepatomas in black South Africans are
usually multifocal and grow rapidly. Those
black patients who entered the trial, however,
did not have a shorter survival than patients who
were white or of mixed race, so their inclusion
is unlikely to have biased the results. It is more
important that the median survival was only 50
days, half of that reported for two groups of
Japanese patients: about 100 days for 693
consecutive patients assessed as unsuitable for
surgery and about 105 days for 100 patients
selected as unsuitable for any treatment.

Moreover, it has been suggested that European
patients with hepatoma may have an even better
prognosis. The short survival of patients in
this study may mean that our conclusions do not
apply to other patients with hepatomas.

In this study chemotherapy with 5-epidoxo-
rubicin emulsified in lipiodol did not improve
survival and increased hospital stay in patients
with hepatoma. Although this trial is small, the
likelihood that it failed to detect a clinically
useful improvement in survival caused by treat-
ment is quite low. The patients studied, how-
ever, had a short survival time so this conclusion
may not be valid for all patients with this
tumour. The treatment was not applicable to half
of the patients, usually because the tumour was
too advanced at the time of diagnosis.

We are grateful to Dr Deborah Bradshaw (Centre for Epidemiologi-
ical Research in Southern Africa, Medical Research Council of
South Africa) for calculating the number of patients to be studied
and for assessing the effect of the trial's size on the validity of the
results.

These data were presented in part at the July 1992 meeting of
the South African Gastroenterology Society.

1 Kanematsu T, Inoukuchi K, Sugimachi K, Furuta T, Sonoda
T, Tanmura S, et al. Selective effects of lipiodolised antitumor
2 Kanematsu T, Furuta T, Takenaka K, Matsumura T, Yoshida
Y, Nishizaki T, et al. A 5-year experience of lipiodolisation:
selective regional chemotheraphy for 200 patients with
3 Kirk S, Bhumgart R, Craig B, Rosen A, Terblanche J, Spence
RAJ. Irresectable hepatoma treated by intrahepatic iodized
oil doxorubicin hydrochloride: Initial results. Surgery 1991;
4 Okuda K. Diagnosis and non-surgical treatment of hepato-
5 Gail M, Gart J. The determination of sample sizes for use
with the exact conditional test in 2×2 comparative trials.
6 Smith AH, Bases MN. Confidence limit analyses should
replace power calculations in the interpretation of epidemi-
7 Okuda K, Obitsu T, Obata H, Yomimatsu M, Okazaki N,
Hasegawa H, et al. Natural history of hepatocellular
carcinoma and prognosis in relation to treatment. Study of
8 Pelletier G, Roche A, Ink O, Anciaux ML, Derby S, Rouquier
P, et al. A randomised trial of hepatic arterial choemo-
embolisation in patients with unresectable hepatocellular
carcinoma. A randomised controlled trial. Gastroenterology 1989;
treatment in patients with unresectable hepatocellular
carcinoma — A randomised controlled trial. Gastroenterology
10 Wendis JR, Blum HE. Primary hepatocellular carcinoma.
11 Anonymous. Hepatocellular cancer: differences between high
and low incidence regions [Editorial]. Lancet 1987; ii:
1183-4.
12 Nagasu N, Yukaya H, Hamada T, Hirose S, Kanashima R,
Inoukuchi K. The natural history of hepatocellular
carcinoma. A study of 100 untreated cases. Cancer 1984;
54: 1461-5.
13 Forbes A, Williams R. Chemotherapy and radiotherapy of
malignant hepatic tumours. Baillieres Clin Gastroenterol
Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma.

M V Madden, J E Krige, S Bailey, S J Beningfield, C Geddes, I D Werner and J Terblanche

*Gut* 1993 34: 1598-1600
doi: 10.1136/gut.34.11.1598

Updated information and services can be found at:
http://gut.bmj.com/content/34/11/1598

**Email alerting service**

*These include:*
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Hepatic cancer (474)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/